公司資料
Arcutis Biotherapeutics 股價、新聞與催化劑
- 股票代碼:
- ARQT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
25.61 USD (-2.21%)
收盤價
最後更新: 2026年8月17日
2.6B USD
市值
股價為何變動
As of Aug 17, 2026, ARQT closed down 2.21% at $25.61. No new same-company headline was identified in the current news window.
公司概覽
Medical Dermatology
Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology.
ZORYVE Franchise
ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
Pediatric Expansion
Arcutis is seeking to extend ZORYVE cream to infants with atopic dermatitis and ZORYVE foam to younger children with scalp and body plaque psoriasis.
New ZORYVE Indications
Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.
ARQ-234
ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
未來催化劑
- FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA.
- Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026.
- Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。